Sunday, May 09, 2021 9:08:00 AM
edit, sorry Senti this response was to iwasadiver's post you responded to.
"I just feel too many here are building up ASCO to be this big event and I simply don’t think that’s rational and I hate to see the fallout of a disappointed group of shareholders"
I am afraid this "fallout" will happen with some shareholders regardless. I don't believe it will necessarily be down to missing any ASCO deadline, but more about us passing 8+ month since Data lock. Unless the company provide a realistic timeline to TLD by ASCO it would not surprise me if we do see some degree of sell off. Of course many longs will 'stay the course' but not providing a credible plan along with continue silence could be too much for some.
It is intriguing however, that not only is LL presenting on the 18th May but that the title is "Brain tumor clinical trial update"
Therefore, there is hope that we get TLD soon regardless of how they announce it. If we don't get news before the ASM, we would have to get it on the 18th prior to LL's talk if she intends to discuss results or unblinded data. Difficult to imagine she will just provide the same blinded updates we have had to date but who knows?
Virtual Visiting Professor: Brain Tumor Clinical Trial Update
Tuesday, May 18, 6:00–7:00 pm CT
Faculty: Amy Heimberger, Linda Liau, Ian Parney
Moderator: Edjau Nduom
https://www.cns.org/upcoming-live-webinars
"I just feel too many here are building up ASCO to be this big event and I simply don’t think that’s rational and I hate to see the fallout of a disappointed group of shareholders"
I am afraid this "fallout" will happen with some shareholders regardless. I don't believe it will necessarily be down to missing any ASCO deadline, but more about us passing 8+ month since Data lock. Unless the company provide a realistic timeline to TLD by ASCO it would not surprise me if we do see some degree of sell off. Of course many longs will 'stay the course' but not providing a credible plan along with continue silence could be too much for some.
It is intriguing however, that not only is LL presenting on the 18th May but that the title is "Brain tumor clinical trial update"
Therefore, there is hope that we get TLD soon regardless of how they announce it. If we don't get news before the ASM, we would have to get it on the 18th prior to LL's talk if she intends to discuss results or unblinded data. Difficult to imagine she will just provide the same blinded updates we have had to date but who knows?
Virtual Visiting Professor: Brain Tumor Clinical Trial Update
Tuesday, May 18, 6:00–7:00 pm CT
Faculty: Amy Heimberger, Linda Liau, Ian Parney
Moderator: Edjau Nduom
https://www.cns.org/upcoming-live-webinars
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
